Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...
Management implemented a turnaround plan in 2024. This year's sales growth has been promising. The stock's valuation has become richer, but remains attractive compared to the overall market. But that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results